RecruitingPhase 1NCT06859853

A Study to Evaluate MWN109 Injection in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWN109 Injection in Healthy Subjects

Sponsor

Shanghai Minwei Biotechnology Co., Ltd

Enrollment

72 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Overweight or obese

Summary

This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Subcutaneous single and mutiple dose for people with overweight or obese. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.